Last reviewed · How we verify
Transdermal estrogen
Transdermal estrogen delivers estrogen hormone through the skin to replace deficient estrogen levels in postmenopausal women.
Transdermal estrogen delivers estrogen hormone through the skin to replace deficient estrogen levels in postmenopausal women. Used for Vasomotor symptoms of menopause (hot flashes, night sweats), Vulvar and vaginal atrophy, Osteoporosis prevention in postmenopausal women.
At a glance
| Generic name | Transdermal estrogen |
|---|---|
| Also known as | Transdermal estradiol, Climara, Divigel, Estrodiol Gel, EstroGel |
| Sponsor | University of Utah |
| Drug class | Hormone replacement therapy (HRT) |
| Target | Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
The patch formulation allows estrogen to permeate through the skin and enter systemic circulation, bypassing first-pass hepatic metabolism. This provides steady-state hormone replacement to alleviate menopausal symptoms and provide long-term health benefits. Estrogen acts on estrogen receptors throughout the body to regulate vasomotor, bone, cardiovascular, and cognitive functions.
Approved indications
- Vasomotor symptoms of menopause (hot flashes, night sweats)
- Vulvar and vaginal atrophy
- Osteoporosis prevention in postmenopausal women
- Moderate to severe menopausal symptoms
Common side effects
- Breast tenderness
- Headache
- Nausea
- Skin irritation at patch site
- Vaginal bleeding/spotting
- Fluid retention
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Estradiol Supplementation and Rotator Cuff Repair (PHASE2)
- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial (PHASE2)
- COMPASS - COpenhagen MenoPAuSe Study (PHASE2)
- Impact of Estradiol on Endothelial Function in Peri-Menopausal Women (PHASE4)
- MHT and Liver Function in Postmenopausal Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal estrogen CI brief — competitive landscape report
- Transdermal estrogen updates RSS · CI watch RSS
- University of Utah portfolio CI